AbbVie settles longstanding trade secret dispute with Evolus
23-02-2021
AbbVie and Mylan agree Humira licensing deal
18-07-2018
AbbVie and Besins to pay FTC $448m in sham litigation case
02-07-2018
jansucko / iStockphoto.com
AbbVie and Alphabet have committed a further $1 billion to fund Alphabet-backed Calico’s development of new therapies for patients with age-related diseases.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AbbVie, Calico, Alphabet, age-related diseases, life sciences, collaboration, neurodegeneration, cancer
